bioAffinity Technologies (NASDAQ:BIAF) announced on March 10, 2026, the launch of a large longitudinal clinical study involving 2,000 patients to evaluate the performance of its CyPath® Lung ...
In a recent opinion piece published in the journal Trends in Cancer, researchers examined the rising global burden of lung cancer in people with no history of smoking. This phenomenon requires its own ...
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Charles Swanton and his colleagues at London’s Francis Crick Institute and University College London, ...
NeXT Personal identifies circulating tumor DNA in 81% of early-stage lung adenocarcinoma cases, offering potential for better disease stratification and outcome prediction. Study: Ultrasensitive ctDNA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results